Ultragenyx Pharmaceutical (RARE) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to 0.01.
- Ultragenyx Pharmaceutical's Equity Ratio fell 9658.74% to 0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.01, marking a year-over-year decrease of 9658.74%. This contributed to the annual value of 0.17 for FY2024, which is 807.15% down from last year.
- Latest data reveals that Ultragenyx Pharmaceutical reported Equity Ratio of 0.01 as of Q3 2025, which was down 9658.74% from 0.12 recorded in Q2 2025.
- Over the past 5 years, Ultragenyx Pharmaceutical's Equity Ratio peaked at 0.66 during Q1 2021, and registered a low of 0.01 during Q3 2025.
- Moreover, its 5-year median value for Equity Ratio was 0.23 (2024), whereas its average is 0.3.
- As far as peak fluctuations go, Ultragenyx Pharmaceutical's Equity Ratio skyrocketed by 78018.27% in 2024, and later tumbled by 9658.74% in 2025.
- Over the past 5 years, Ultragenyx Pharmaceutical's Equity Ratio (Quarter) stood at 0.61 in 2021, then plummeted by 62.36% to 0.23 in 2022, then dropped by 19.01% to 0.18 in 2023, then decreased by 8.07% to 0.17 in 2024, then crashed by 95.47% to 0.01 in 2025.
- Its last three reported values are 0.01 in Q3 2025, 0.12 for Q2 2025, and 0.11 during Q1 2025.